Sort
23,748 grants matching “melanoma”
Dendritic Cell Vaccination During Lymphoid Reconstitution
$602,707Jeffrey S Weber · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2007 · CA
Spectrum of clinical phenotype of the BAP1-tumor predisposition syndrome (BAP1-TPDS)
$602,616Mohamed H. Abdel-Rahman · Ohio State University · R01 · FY2025 · CA
OCULAR MELANOMA
$602,423University Of Pennsylvania · U10 · FY2000 · EY
VPS72 controls Treg cell stability and adaptation to tumor microenvironment
$602,346Qing-Sheng Mi · Henry Ford Health + Michigan State University Health Sciences · R01 · FY2024 · CA
Regulation of resistance to CDK4/6 inhibitor in breast cancer
$602,262Wenge Zhu · George Washington University · R01 · FY2024 · CA
Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis
$602,227Jenny J Yang · Inlighta Biosciences, Llc · R42 · FY2017 · CA
Multimeric Ligands for Targeting Melanoma
$602,202David L Morse · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2011 · CA
NCI National Clinical Trials Network-Network Lead Academic Participating Site
$602,112Lawrence E Flaherty · Wayne State University · U10 · FY2016 · CA
Genetic Epidemiology of Melanoma
$602,074David E E Elder · University Of Pennsylvania · R01 · FY2008 · CA
Skin Cancer Prevention in a Pediatric Population
$601,762University Of Colorado Denver · R01 · FY2003 · CA
Project 3 - Modulation of Antiviral Immunity and T cell Exhaustion by Inhibitory Receptors
$601,739E. John Wherry · University Of Pittsburgh At Pittsburgh · P01 · FY2025 · AI
Impact of Melanoma Genetic Testing on Health Cognitions and Prevention Behaviors
$601,560Sancy Ann Leachman · University Of Utah · R01 · FY2012 · CA
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
$601,546Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2022 · CA
Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds
$601,292Gloria M. Petersen · Mayo Clinic Rochester · R01 · FY2018 · CA
REVEALING SPATIAL TRANSCRIPTOMIC AND PROTEOMIC SHIFTS IN TUMOR-INFILTRATING IMMUNOCYTES: CHARTING A PATH TO ENHANCED MELANOMA THERAPEUTICS
$601,272Jackson Laboratory · · FY2025 · Defense Health Agency
Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment
$601,253Yubin Miao · University Of Colorado Denver · R01 · FY2024 · CA
Using Clonal and Non-Clonal UV Signature Mutations to Predict Skin Cancer Risk
$601,191Douglas E Brash · Yale University · R01 · FY2020 · CA
Primary Project
$601,082Eva M Sevick-Muraca · University Of Texas Hlth Sci Ctr Houston · U54 · FY2010 · CA
Basic applications for total-body PET in oncology
$601,074Lorenzo Nardo · University Of California At Davis · R01 · FY2023 · CA
Molecular mechanisms underlying lineage plasticity in prostate cancer
$601,022Himisha Beltran · Dana-Farber Cancer Inst · R37 · FY2025 · CA
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
$600,913Efstathios Karathanasis · Case Western Reserve University · R01 · FY2023 · CA
Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy
$600,878Cheng Zhu · Georgia Institute Of Technology · U01 · FY2024 · CA
Multimeric Ligands for Targeting Melanoma
$600,715David L Morse · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2012 · CA
NCI National Clinical Trials Network-Network Lead Academic Participating Site
$600,573Lawrence E Flaherty · Wayne State University · U10 · FY2017 · CA
Mechanisms that couple irregular development of fetal melanoblasts to premature exhaustion of adult melanocyte stem cells
$600,533Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2021 · AR